Validation of DN4 as a screening tool for neuropathic pain in painful diabetic polyneuropathy

Diabetic Medicine

Volumn 29, Issue 5, 2012, Pages 578-585

  Spallone, V ^a   Morganti, R ^a   D'Amato, C ^a   Greco, C ^a   Cacciotti, L ^a   Marfia, G A ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Diabetes; Diagnosis; DN4; Neuropathic pain; Painful diabetic neuropathy

Indexed keywords

ADULT; AGED; ARTICLE; BRAIN ELECTROPHYSIOLOGY; CLINICAL ASSESSMENT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC NEUROPATHY; DIAGNOSTIC ACCURACY; DOULEUR NEUROPATHIQUE EN 4 QUESTIONNAIRE; FEMALE; HUMAN; INTERVIEW; MAJOR CLINICAL STUDY; MALE; MCGILL PAIN QUESTIONNAIRE; MEDICAL HISTORY; NERVE CONDUCTION; NEUROPATHIC PAIN; PREDICTIVE VALUE; QUANTITATIVE ANALYSIS; QUESTIONNAIRE; RATING SCALE; SCORING SYSTEM; SCREENING; SENSITIVITY AND SPECIFICITY; SINGLE BLIND PROCEDURE; SYMPTOM; VALIDATION STUDY;

CROSS-SECTIONAL STUDIES; DIABETIC NEUROPATHIES; FEMALE; HUMANS; ITALY; MALE; MASS SCREENING; MIDDLE AGED; NEURALGIA; PAIN MEASUREMENT; QUESTIONNAIRES; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; VIBRATION;

EID: 84859824037     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2011.03500.x     Document Type: Article

References (30)

1. Tesfaye S, Boulton AJ, Dyck PJ, Freeman R, Horowitz M, Kempler P et al. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care 2010; 33: 2285-2293.
2. Daousi C, MacFarlane IA, Woodward A, Nurmikko TJ, Bundred PE, Benbow SJ. Chronic painful peripheral neuropathy in an urban community: a controlled comparison of people with and without diabetes. Diabet Med 2004; 21: 976-982.
3. Davies M, Brophy S, Williams R, Taylor A. The prevalence, severity and impact of painful diabetic peripheral neuropathy in type 2 diabetes. Diabetes Care 2006; 29: 1518-1522.
4. Ziegler D, Rathmann W, Dickhaus T, Meisinger C, Mielck A, KORA Study Group. Neuropathic pain in diabetes, prediabetes and normal glucose tolerance: the MONICA/KORA Augsburg Surveys S2 and S3. Pain Med 2009; 10: 393-400.
5. Van Acker K, Bouhassira D, De Bacquer D, Weiss S, Matthys K, Raemen H et al. Prevalence and impact on quality of life of peripheral neuropathy with or without neuropathic pain in type 1 and type 2 diabetic patients attending hospital outpatients clinics. Diabetes Metab 2009; 35: 206-213.
6. Gore M, Brandenburg NA, Hoffman DL, Tai KS, Stacey B. Burden of illness in painful diabetic peripheral neuropathy: the patients' perspectives. J Pain 2006; 7: 892-900.
7. Argoff CE, Backonja MM, Belgrade MJ, Bennett GJ, Clark MR, Cole BE et al. Consensus guidelines: treatment planning and options. Diabetic peripheral neuropathic pain. Mayo Clin Proc 2006; 81: S12-S25.
8. Treede RD, Jensen TS, Campbell JN, Cruccu G, Dostrovsky JO, Griffin JW et al. Neuropathic pain: redefinition and a grading system for clinical and research purposes. Neurology 2008; 70: 1630-1635.
9. Boulton AJ, Vinik AI, Arezzo JC, Bril V, Feldman EL, Freeman R et al. Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care 2005; 28: 956-962.
10. England JD, Gronseth GS, Franklin G, Miller RG, Asbury AK, Carter GT et al. A report of the American Academy of Neurology, the American Association of Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Neurology 2005; 64: 199-207.
11. Cruccu G, Sommer C, Anand P, Attal N, Baron R, Garcia-Larrea L et al. EFNS guidelines on neuropathic pain assessment: revised 2009. Eur J Neurol 2010; 17: 1010-1018.
12. Dworkin RH, Turk DC, Farrar JT, Haythornthwaite JA, Jensen MP, Katz NP et al. Core outcome measures for chronic pain clinical trials: IMMPACT recommendations. Pain 2005; 113: 9-19.
13. Bennett MI, Attal N, Backonja MM, Baron R, Bouhassira D, Freynhagen R et al. Using screening tools to identify neuropathic pain. Pain 2007; 127: 199-203.
14. Bouhassira D, Attal N, Alchaar H, Boureau F, Brochet B, Bruxelle J et al. Comparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagnostic questionnaire (DN4). Pain 2005; 114: 29-36.
15. Perez C, Galvez R, Huelbes S, Insausti J, Bouhassira D, Diaz S et al. Validity and reliability of the Spanish version of the DN4 (Douleur Neuropathique 4 questions) questionnaire for differential diagnosis of pain syndromes associated to a neuropathic or somatic component. Health Qual Life Outcomes 2007; 5: 66.
16. Van Seventer R, Vos C, Meerding W, Mear I, Le Gal M, Bouhassira D et al. Linguistic validation of the DN4 for use in international studies. Eur J Pain 2010; 14: 58-63.
17. Miralles-García JM, de Pablos-Velasco P, Cabrerizo L, Pérez M, López-Gómez V, Sociedad Española de Endocrinología y Nutrición. Prevalence of distal diabetic polyneuropathy using quantitative sensory methods in a population with diabetes of more than 10years' disease duration. Endocrinol Nutr 2010; 57: 414-420.
18. Halawa MR, Karawagh A, Zeidan A, Mahmoud AE, Sakr M, Hegazy A. Prevalence of painful diabetic peripheral neuropathy among patients suffering from diabetes mellitus in Saudi Arabia. Curr Med Res Opin 2010; 26: 337-343.
19. Feldman EL, Stevens MJ, Thomas PK, Brown MB, Canal N, Greene DA. A practical two-step quantitative clinical and electrophysiological assessment for the diagnosis and staging of diabetic neuropathy. Diabetes Care 1994; 17: 1281-1289.
20. Spallone V, Morganti R, D'Amato C, Cacciotti L, Fedele T, Maiello MR et al. Clinical correlates of painful diabetic neuropathy and relationship of neuropathic pain with sensorimotor and autonomic nerve function. Eur J Pain 2011; 15: 153-160.
21. Bril V, Perkins BA. Comparison of vibration perception thresholds obtained with the Neurothesiometer and the CASE IV and relationship to nerve conduction studies. Diabetic Med 2002; 19: 661-666.
22. Bax G, Fagherazzi C, Piarulli F, Nicolucci A, Fedele D. Reproducibility of Michigan Neuropathy Screening Instrument (MNSI). A comparison with tests using the vibratory and thermal perception thresholds. Diabetes Care 1996; 19: 904-905.
23. Stålberg E, Falck B, Gilai A, Jabre J, Sonoo M, Todnem K. Standards for quantification of EMG and neurography. The International Federation of Clinical Neurophysiology. Electroencephalogr Clin Neurophysiol Suppl 1999; 52: 213-220.
24. Dyck PJ, Karnes JL, O'Brien PC, Litchy WJ, Low PA, Melton LJ 3rd. The Rochester Diabetic Neuropathy Study: reassessment of tests and criteria for diagnosis and staged severity. Neurology 1992; 42: 1164-1170.
25. Melzack R. The short-form McGill Pain Questionnaire. Pain 1987; 30: 191-197.
26. Caraceni A, Mendoza TR, Mencaglia E, Barattella C, Edwards K, Forjaz MJ et al. A validation study of an Italian version of the Brief Pain Inventory (Breve Questionario per la Valutazione del Dolore). Pain 1996; 65: 87-92.
27. Yuan RY, Sheu JJ, Yu JM, Chen WT, Tseng IJ, Chang HH et al. Botulinum toxin for diabetic neuropathic pain: a randomized double-blind cross-over trial. Neurology 2009; 72: 1473-1478.
28. Padua L, Briani C, Jann S, Nobile-Orazio E, Pazzaglia C, Morini A et al. Validation of the Italian version of the Neuropathic Pain Symptom Inventory in peripheral nervous system diseases. Neurol Sci 2009; 2: 99-106.
29. Scholz J, Mannion RJ, Hord DE, Griffin RS, Rawal B, Zheng H et al. A novel tool for the assessment of pain: validation in low back pain. PLoS Med 2009; 6: e1000047.
30. Unal-Cevik I, Sarioglu-Ay S, Evcik D. A comparison of the DN4 and LANSS questionnaires in the assessment of neuropathic pain: validity and reliability of the Turkish version of DN4. J Pain 2010; 11: 1129-1135.